Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Jak2 tyrosine kinase inhibitor prevents cell proliferation in ALL cells in vitro

Sep. 29, 1999

SuperGen acquires decitabine from Pharmachemie

Sep. 28, 1999

Oxford GlycoSciences presents preliminary clinical trial results for OGT-719 at ECCO 10

Sep. 28, 1999

Satraplatin is well tolerated but only marginally effective in cervical cancer

Sep. 28, 1999

Phase I results of Bavarian Nordic's novel pancreatic cancer therapy reported at ECCO 10

Sep. 28, 1999

Paclitaxel/doxorubicin is superior to standard first-line therapy in metastatic breast cancer

Sep. 28, 1999

DNA-binding agents with a pyrrolylbenzimidazole skeleton claimed by Mitsui Chemicals

Sep. 28, 1999

Eisai, EORTC initiate phase I testing of novel G1-targeting anticancer sulfonamide

Sep. 28, 1999

FDA informs Aronex that Atragen NDA is not approvable

Sep. 27, 1999

Progen initiates phase I trial of anticancer drug PI-88

Sep. 27, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...